C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/13 (2006.01) C07H 1/04 (2006.01) C07H 21/04 (2006.01) C07K 16/10 (2006.01) C07K 19/00 (2006.01) C12N 5/10 (2006.01) C12N 5/12 (2006.01) C12N 15/02 (2006.01) C12N 15/62 (2006.01) C12P 21/08 (2006.01)
Patent
CA 2122044
The present invention provides monoclonal antibodies that are specifically immunoreactive with an HIV-1 gp120 protein or its precursor gp160 protein comprising the amino acid sequence set out in SEQ ID NO: 1, G-P-G-R, and characterized by their ability to neutralize, in vitro, the infection of H9 cells by live HIV-1 strains MN and III B as determined by reverse tran- scriptase, p24, MT-2 and syncytium formation assays. Presently preferred antibody NM-01 isolated from mouse/mouse hybridoma ATCC HB 10726 is further characterized by its capacity to mediate complement-dependent virolysis of HIV-1 particles and antibody-dependent cellular cytotoxicity of HIV-1 infected cells. Antibodies consisting essentially of a human antibody variable region comprising a sequence of amino acids of at least one complementarity determining region of the monoclonal antibody produced by the hydridoma cell line ATCC HB 10726 are specifically disclosed. Pharmaceutical com- positions of the invention are projected to be useful in the passive immunization treatment of animals, especially humans, susceptible to or infected with HIV-1.
G. Ronald Bell & Associates
Nissin Shokuhin Kabushiki Kaisha
Srd Pharmaceuticals Incorporated
LandOfFree
Hiv immunotherapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hiv immunotherapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hiv immunotherapeutics will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1541505